» Articles » PMID: 10595361

Use of Minimally Modified Antisense Oligonucleotides for Specific Inhibition of Gene Expression

Overview
Journal Methods Enzymol
Specialty Biochemistry
Date 1999 Dec 14
PMID 10595361
Citations 11
Authors
Affiliations
Soon will be listed here.
Citing Articles

Selection of Membrane RNA Aptamers to Amyloid Beta Peptide: Implications for Exosome-Based Antioxidant Strategies.

Janas T, Sapon K, Stowell M, Janas T Int J Mol Sci. 2019; 20(2).

PMID: 30642129 PMC: 6359565. DOI: 10.3390/ijms20020299.


Quantitative PCR analysis of DNA aptamer pharmacokinetics in mice.

Perschbacher K, Smestad J, Peters J, Standiford M, Denic A, Wootla B Nucleic Acid Ther. 2014; 25(1):11-9.

PMID: 25536292 PMC: 4296750. DOI: 10.1089/nat.2014.0515.


Aptamers as both drugs and drug-carriers.

Ashrafuzzaman M Biomed Res Int. 2014; 2014:697923.

PMID: 25295268 PMC: 4177733. DOI: 10.1155/2014/697923.


Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents.

Rohloff J, Gelinas A, Jarvis T, Ochsner U, Schneider D, Gold L Mol Ther Nucleic Acids. 2014; 3:e201.

PMID: 25291143 PMC: 4217074. DOI: 10.1038/mtna.2014.49.


First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.

Sen M, Thomas S, Kim S, Yeh J, Ferris R, Johnson J Cancer Discov. 2012; 2(8):694-705.

PMID: 22719020 PMC: 3668699. DOI: 10.1158/2159-8290.CD-12-0191.